Israel Englander Bolt Biotherapeutics, Inc. Transaction History

Millennium Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$1.01 - $1.4 $1,061 - $1,471	-1,051 Reduced 2.24%	45,956 $64,000
Q4 2023 Feb 14, 2024	SELL	$0.85 - $1.12 $56,934 - $75,019	-66,982 Reduced 58.76%	47,007 $52,000
Q2 2023 Aug 14, 2023	SELL	$1.27 - $1.95 $166,905 - $256,272	-131,422 Reduced 53.55%	113,989 $145,000
Q1 2023 May 15, 2023	BUY	$1.29 - $1.66 $2,592 - $3,336	2,010 Added 0.83%	245,411 $341,000
Q4 2022 Feb 14, 2023	BUY	$1.26 - $1.51 $157,527 - $188,783	125,022 Added 105.61%	243,401 $316,000
Q3 2022 Nov 14, 2022	SELL	$1.48 - $2.61 $108,745 - $191,774	-73,477 Reduced 38.3%	118,379 $175,000

19.1M

Ticker BOLT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,641,500
Market Cap $20.7M
Description
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-e...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.